Patents by Inventor Ziyang Zhong
Ziyang Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060183160Abstract: The invention concerns a novel ?-secretase, a method of partially purifying this novel ?-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel ?-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.Type: ApplicationFiled: April 12, 2006Publication date: August 17, 2006Applicant: Scios, Inc.Inventors: Ziyang Zhong, Barbara Cordell, Diana Quon, Yu-Wang Liu, Qiang Xu, Frauke Schimmoller, Paul Hyslop, Edward Johnstone, Sheila Little, Stephen Queener, Tinggui Yin
-
Patent number: 7087399Abstract: The invention concerns a novel ?-secretase, a method of partially purifying this novel ?-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel ?-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.Type: GrantFiled: May 9, 2000Date of Patent: August 8, 2006Assignee: Scios, Inc.Inventors: Ziyang Zhong, Barbara Cordell, Diana Hom Quon, Yu-Wang Liu, Qiang Xu, Frauke Schimmöller, Paul Andrew Hyslop, Edward Marion Johnstone, Sheila Parks Little, Steven Wyatt Queener, Tinggui Yin
-
Publication number: 20060088932Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: December 10, 2003Publication date: April 27, 2006Applicant: Chiron CorporationInventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
-
Patent number: 7033812Abstract: The invention concerns a novel ?-secretase, a method of partially purifying this novel ?-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel ?-secretase has an estimated molecular weight of about 32–39 kDa or 22–26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5–7.0.Type: GrantFiled: December 18, 2003Date of Patent: April 25, 2006Assignees: Scios Inc., Eli Lilly and CompanyInventors: Ziyang Zhong, Barbara Cordell, Diana Hom Quon, Yu-Wang Liu, Qiang Xu, Frauke Schimmöller, Paul Andrew Hyslop, Edward Marion Johnstone, Sheila Parks Little, Steven Wyatt Queener, Tinggui Yin
-
Publication number: 20050277682Abstract: Formulations of desoxyepothilones are stable before and after dilution into aqueous media.Type: ApplicationFiled: March 15, 2005Publication date: December 15, 2005Inventors: Peter Licari, Ziyang Zhong, Indu Isaacs, John Augustine
-
Publication number: 20050256097Abstract: A pharmaceutical solution formulation containing 17-AAG in an amount of up to 15 mg/mL dissolved in a vehicle comprising (i) a first component that is ethanol, in an amount of between about 40 and about 60 volume %; (ii) a second component that is a polyethoxylated castor oil, in an amount of between about 15 to about 50 volume %; and (iii) a third component that is selected from the group consisting of propylene glycol, PEG 300, PEG 400, glycerol, and combinations thereof, in an amount of between about 0 and about 35 volume %.Type: ApplicationFiled: May 5, 2005Publication date: November 17, 2005Applicant: Kosan Biosciences, Inc.Inventors: Ziyang Zhong, Peter Licari
-
Publication number: 20050048511Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: October 20, 2003Publication date: March 3, 2005Applicant: Chiron CorporationInventors: Stephen Harrison, John Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Fang, Doris Coit, Steve Nguyen, Angelica Medina-Selby
-
Publication number: 20040132159Abstract: The invention concerns a novel &bgr;-secretase, a method of partially purifying this novel &bgr;-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel &bgr;-secretase has an estmated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.Type: ApplicationFiled: December 18, 2003Publication date: July 8, 2004Inventors: Ziyang Zhong, Barbara Cordell, Diana Hom Quon, Yu-Wang Liu, Qiang Xu, Frauke Schimmoller, Paul Andrew Hyslop, Edward Marion Johnstone, Sheila Parks Little, Stephen Wyatt Queener, Tinggui Yin
-
Patent number: 6716624Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: July 31, 2002Date of Patent: April 6, 2004Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Publication number: 20030077798Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: July 31, 2002Publication date: April 24, 2003Applicant: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 6465231Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: July 25, 2001Date of Patent: October 15, 2002Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Publication number: 20020082408Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: ApplicationFiled: July 25, 2001Publication date: June 27, 2002Inventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 6303340Abstract: A method is described for producing a peptide having a pI above 8 or below 5 wherein the peptide is expressed as a fusion protein in which it is linked to a fusion partner through an acid cleavage site. The peptide is released from the fusion partner by acid cleavage in the absence of chaotrope. The fusion partner and its acid cleavage products, if any, have a net charge sufficiently different from that of the desired peptide to allow isolation of the peptide by ion-exchange chromatography.Type: GrantFiled: July 8, 1999Date of Patent: October 16, 2001Assignee: Scios Inc.Inventors: N. Stephen Pollitt, Douglas I. Buckley, Peter A. Stathis, Taymar E. Hartman, Ziyang Zhong